Literature DB >> 24906621

Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer.

Eva Pastille1, Katrin Bardini1, Diana Fleissner1, Alexandra Adamczyk1, Annika Frede1, Munisch Wadwa1, Dorthe von Smolinski2, Stefan Kasper3, Tim Sparwasser4, Achim D Gruber2, Martin Schuler5, Shimon Sakaguchi6, Axel Roers7, Werner Müller8, Wiebke Hansen1, Jan Buer1, Astrid M Westendorf9.   

Abstract

Regulatory T cells (Treg) are supportive to cancer development in most tissues, but their role in colitis-associated colon cancer (CAC) remains unclear. In this study, we investigated the role of CD4(+)Foxp3(+) Treg in a mouse model of CAC and in patients with colon cancer. These Treg were increased strongly in number in a mouse model of CAC and in the peripheral blood of patients with colon cancer, exhibiting an activated phenotype as defined by elevated expression of GARP, CD103, CTLA-4, and IL10, along with an increased suppressive effect on the proliferation and Th1 cytokine expression of CD4(+)CD25(-) responder T cells ex vivo. Transient ablation of CD4(+)Foxp3(+) Treg during tumor development in the CAC model suppressed tumor outgrowth and distribution, accompanied by an increased number of CD8(+)IFNγ/granzyme B-producing effector T cells. Conversely, inactivation of IL10 in Treg did not elevate the antitumor response but instead further boosted tumor development. Our results establish a tumor-promoting function for Treg during CAC formation, but they also suggest that a selective, transient ablation of Treg can evoke antitumor responses, with implications for immunotherapeutic interventions in patients with CAC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 24906621     DOI: 10.1158/0008-5472.CAN-13-3065

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Authors:  Sarah Nikiforow; Haesook T Kim; Heather Daley; Carol Reynolds; Kyle Thomas Jones; Philippe Armand; Vincent T Ho; Edwin P Alyea; Corey S Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

Review 2.  High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cancer Immunol Immunother       Date:  2016-02-24       Impact factor: 6.968

3.  GARP Dampens Cancer Immunity by Sustaining Function and Accumulation of Regulatory T Cells in the Colon.

Authors:  Mohammad Salem; Caroline Wallace; Maria Velegraki; Anqi Li; Ephraim Ansa-Addo; Alessandra Metelli; Hyunwoo Kwon; Brian Riesenberg; Bill Wu; Yongliang Zhang; Silvia Guglietta; Shaoli Sun; Bei Liu; Zihai Li
Journal:  Cancer Res       Date:  2019-01-23       Impact factor: 12.701

4.  A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.

Authors:  Joseph M Tuscano; Emanual Maverakis; Susan Groshen; Denice Tsao-Wei; Guillaume Luxardi; Alexander A Merleev; Anne Beaven; John F DiPersio; Leslie Popplewell; Robert Chen; Mark Kirschbaum; Mark A Schroeder; Edward M Newman
Journal:  Clin Cancer Res       Date:  2019-09-03       Impact factor: 12.531

Review 5.  Immunosuppression associated with chronic inflammation in the tumor microenvironment.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Carcinogenesis       Date:  2015-09-08       Impact factor: 4.944

6.  Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells.

Authors:  Caroline Theresa Seebauer; Stefan Brunner; Gabriel Glockzin; Pompiliu Piso; Petra Ruemmele; Hans-Juergen Schlitt; Edward Kenneth Geissler; Stefan Fichtner-Feigl; Rebecca Kesselring
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110

7.  MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer.

Authors:  Kandy T Velázquez; Reilly T Enos; Jamie L McClellan; Taryn L Cranford; Ioulia Chatzistamou; Udai P Singh; Mitzi Nagarkatti; Prakash S Nagarkatti; Daping Fan; E Angela Murphy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-07       Impact factor: 4.052

8.  Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells.

Authors:  Mingyang Song; Reiko Nishihara; Yin Cao; Eunyoung Chun; Zhi Rong Qian; Kosuke Mima; Kentaro Inamura; Yohei Masugi; Jonathan A Nowak; Katsuhiko Nosho; Kana Wu; Molin Wang; Edward Giovannucci; Wendy S Garrett; Charles S Fuchs; Shuji Ogino; Andrew T Chan
Journal:  JAMA Oncol       Date:  2016-09-01       Impact factor: 31.777

Review 9.  From mice to humans: developments in cancer immunoediting.

Authors:  Michele W L Teng; Jerome Galon; Wolf-Herman Fridman; Mark J Smyth
Journal:  J Clin Invest       Date:  2015-08-04       Impact factor: 14.808

10.  Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer.

Authors:  Renuka Subramaniam; Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  Cancer Res Front       Date:  2016-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.